Clinical trials: HIV Seropositivity
Influenza
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients
The purpose of this study is to evaluate the antibody response in dialysis patents to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine (Formulation 2011-2012).
- Trial name
- NCT01512056
- Testing
- AdimFlu-S
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Cheng-Kung University Hospital
HIV Seropositivity, Acquired Immunodeficiency Syndrome
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation
HIV virus is an etiologic agent of ( AIDS ) immunodeficiency syndrome . It is known that the estimated rate of transfer from mother to baby is 25% to 45%, pregnancy rate is 5-10%, pregnancy rate is 15-20% and in lactation period…
- Conditions
- HIV Seropositivity, Acquired Immunodeficiency Syndrome, Pregnancy, High Risk
- Trial name
- NCT03777371
- Testing
- Anti HIV Seropositive Pregnant Women
- Volunteers
- 128 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
HIV Infections
Metabolic Abnormalities - HIV Infected and Uninfected Males
To assess whether there exist significant differences in glucose metabolism, lipids, lactate, body composition, and bone density between HIV-infected and uninfected young men.
- Trial name
- NCT00260936
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, HIV-1-infection
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD)…
- Conditions
- HIV Infections, HIV-1-infection, HIV Seropositivity
- Trial name
- NCT03311945
- Testing
- Raltegravir, Lamivudine
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Judit Pich
HIV Enteropathy, Diarrhea With HIV
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.
- Trial name
- NCT01374490
- Testing
- Crofelemer
- Where
- 21 sites in United States
- Volunteers
- 250 people
- Sponsor
- Bausch Health Americas, Inc.
HIV Infections, AIDS
HIV and Kidney Function Study
Current methods to assess kidney function have not been tested in people who have HIV/AIDS population. Given effects of the disease as well as potential effects of the medications, it is possible that the methods currently used…
- Trial name
- NCT00905151
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Tufts Medical Center
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Seropositivity
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
What is known: There are 1.2 million people in the US who meet the indications for PrEP; yet, disparities exist in uptake. For example, only 9% of Black and 16% of Latino individuals, compared to 65% of White individuals, have…
- Trial name
- MOST:PrEP (NCT06334341)
- Testing
- Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment
- Where
- United States
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Dry Eye Syndromes, HIV Seropositivity
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
This study evaluates the use of topical cyclosporine 0.05% and sodium carboxymethylcellulose 0.5% for the treatment of dry eye disease in patients infected with the human immunodeficiency virus.
- Trial name
- NCT00797030
- Testing
- cyclosporine and sodium carboximethycellulose, sodium carboximethycellulose
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Universidade Federal do Rio de Janeiro
COVID-19, HIV Seropositivity
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
COVID-19 has emerged as global pandemic during the past few months, with an unprecedented impact on public health, and society more generally.
- Conditions
- COVID-19, HIV Seropositivity, Tuberculosis, Pulmonary, Tuberculosis Infection
- Trial name
- Core-NB (NCT05268380)
- Testing
- Covid-19, TB and HIV diagnosis
- Where
- Namibia
- Volunteers
- 1,750 people
- Sponsor
- University of Namibia
Human Immunodeficiency Virus Positive or Negative
Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs
The purpose of this study is to understand the effects of decreased functioning of the testes or ovaries on mental performance in males and females using illicit drugs excluding marijuana.
- Trial name
- NCT00245531
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients
The purpose of this study is to compare the efficacy and tolerance of a treatment simplification by a Lopinavir/ritonavir monotherapy versus continuation of current treatment in HIV-infected patients
- Trial name
- KALESOLO (NCT00140751)
- Testing
- Lopinavir/ritonavir (drug)
- Where
- 25 sites in France
- Volunteers
- 186 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infections
Safety and Tolerability of the Vaginal Gel PRO 2000/5
The purpose of this study is to determine whether the vaginal gel PRO 2000/5 causes irritation when used daily. Studies have shown PRO 2000/5 is safe and well tolerated as a vaginal gel in healthy women who are not sexually…
- Trial name
- NCT00006207
- Testing
- PRO 2000
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV+ YMSM
Psychosocial Needs of YMSM
The proposed study will use both qualitative and quantitative research methods (mixed methods) to gather data that will support the eventual development of interventions for young men who have sex with men (YMSM) living with…
- Trial name
- NCT00710671
- Where
- 14 sites in United States
- Volunteers
- 254 people
- Sponsor
- University of North Carolina, Chapel Hill
Household Contacts
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies.
- Trial name
- NCT04543357
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections, Crack Cocaine Use
Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users
The proposed study uses a two-arm randomized experimental design to evaluate the efficacy of a brief, theoretically-guided, "Prevention Care Advocate" intervention with HIV-positive crack users.
- Conditions
- HIV Infections, Crack Cocaine Use, Risky Sexual Behavior
- Trial name
- NCT00447798
- Testing
- Prevention Care Advocate
- Where
- 2 sites in United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Columbia University